Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials

BACKGROUND: Programmed death 1/ligand 1 (PD-1/L1) inhibitors have acceptable antitumor activity in patients with platinum-resistant urothelial cancer (UC). However, the reliability and comparability of the antitumor activity, safety profiles and survival outcomes of different immune checkpoint inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zaishang, Li, Xueying, Lam, Wayne, Cao, Yabing, Han, Hui, Zhang, Xueqi, Fang, Jiequn, Xiao, Kefeng, Zhou, Fangjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047637/
https://www.ncbi.nlm.nih.gov/pubmed/33869015
http://dx.doi.org/10.3389/fonc.2021.629646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047637/
https://www.ncbi.nlm.nih.gov/pubmed/33869015
http://dx.doi.org/10.3389/fonc.2021.629646

Ejemplares similares